These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1182 related articles for article (PubMed ID: 9263351)
1. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Schrör K Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351 [TBL] [Abstract][Full Text] [Related]
2. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188 [TBL] [Abstract][Full Text] [Related]
3. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038 [TBL] [Abstract][Full Text] [Related]
4. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016 [TBL] [Abstract][Full Text] [Related]
5. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977 [TBL] [Abstract][Full Text] [Related]
7. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Weir MR; Sperling RS; Reicin A; Gertz BJ Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311 [TBL] [Abstract][Full Text] [Related]
8. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aspirin in the long-term management of atherothrombosis. Patrono C Haematologica; 2002 Jan; 87(1):6-8. PubMed ID: 11801459 [No Abstract] [Full Text] [Related]
12. Platelet activation in obesity and metabolic syndrome. Santilli F; Vazzana N; Liani R; Guagnano MT; Davì G Obes Rev; 2012 Jan; 13(1):27-42. PubMed ID: 21917110 [TBL] [Abstract][Full Text] [Related]
13. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Halushka MK; Walker LP; Halushka PV Clin Pharmacol Ther; 2003 Jan; 73(1):122-30. PubMed ID: 12545150 [TBL] [Abstract][Full Text] [Related]
14. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo. Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375 [TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894 [TBL] [Abstract][Full Text] [Related]
16. Aspirin as an antithrombotic drug: from the aggregometer to clinical trials. de Gaetano G Verh K Acad Geneeskd Belg; 1990; 52(6):459-71; discussion 471-3. PubMed ID: 2150736 [TBL] [Abstract][Full Text] [Related]
17. Dose- and time-dependent antiplatelet effects of aspirin. Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836 [TBL] [Abstract][Full Text] [Related]
18. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Kobzar G; Mardla V; Samel N Platelets; 2011; 22(5):338-44. PubMed ID: 21557683 [TBL] [Abstract][Full Text] [Related]
19. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341 [TBL] [Abstract][Full Text] [Related]